“Ly, agree, news is coming on all fronts now, ev
Post# of 148179
Cancer has been, and continues go be, the biggest potential indication for leronlimab as a drug and for CYDY as a company. COVID has slowed enrollment of the mTNBC trial, but I don’t doubt results continue to be positive (imaging and laboratory results). Once COVID restrictions are lifted, I believe the mTNBC and basket trial will enroll quicker. If results in the mTNBC trial continue as they have been, the indication will be worth billions alone.